|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our findings are of importance for personalized cancer therapy, such as for patients suffering from specific types of breast tumors with activated EGF receptor-Ras or inactivated JNK pathways.
|
31766464 |
2019 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We found that signal peptide-CUB (complement protein C1r/C1s, Uegf, and Bmp1)-EGF (epidermal growth factor) domain-containing protein 2 (<i>SCUBE2</i>), a tumor suppressor gene, was hypermethylated in breast tumors.
|
31404982 |
2019 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this study, we demonstrate that epidermal growth factor-like 9 (EGFL9) is significantly upregulated in basal-like breast cancer cells and associated with metastatic progression in breast tumor samples.
|
31695034 |
2019 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors.
|
29382783 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
FGF2 and EGF Are Required for Self-Renewal and Organoid Formation of Canine Normal and Tumor Breast Stem Cells.
|
27632571 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The contributions of EGF family ligands and their receptors to breast cancer are complex, and the specific mechanisms through which different ligands regulate breast tumor initiation and growth are not well-defined.
|
26215578 |
2015 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PBX1 regulates a subset of EGF-ERα genes highly expressed in aggressive breast tumours.
|
26215677 |
2015 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Inhibition of EGF/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells.
|
23064031 |
2013 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Stromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors.
|
23689072 |
2013 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our findings suggest that WASp acts to support both the migration of TAMs and the production of EGF, which in concert promote breast tumor metastasis.
|
23911287 |
2013 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
SUMO-deficient (phospho-Ser294) PR gene signatures are significantly associated with human epidermal growth factor 2 (ERBB2)-positive luminal breast tumors and predictive of early metastasis and shortened survival.
|
22697792 |
2012 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells.
|
21390186 |
2011 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Resveratrol modulates MED28 (Magicin/EG-1) expression and inhibits epidermal growth factor (EGF)-induced migration in MDA-MB-231 human breast cancer cells.
|
21942447 |
2011 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We initially confirmed that breast tumour tissues express all five somatostatin receptors (SSTR1-5) and four epidermal growth factor receptors (ErbB1-4).
|
19070659 |
2009 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells.
|
18990689 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
ESR1 and EGF genetic variation in relation to breast cancer risk and survival.
|
18271972 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
On the basis of our results, the action of EGF may include the up-regulation of GPR30 in facilitating a stimulatory role of estrogen, even in ER-negative breast tumor cells.
|
18467441 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women.
|
17940864 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal.
|
17612563 |
2007 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75.
|
16175315 |
2005 |
|
Mammary Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Finally, regulation of phosphorylation of ER-alpha and EGFR may play critical roles in EGF-induced transcriptional activation of WISP-2 gene in breast tumor cells.
|
15798095 |
2005 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells.
|
14676838 |
2004 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells.
|
15272014 |
2004 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c.
|
12531699 |
2003 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, accumulation of transferrin and EGF in the HIP1-transformed cells was increased, and breast tumors that had EGFR expressed also had HIP1 upregulated.
|
12781365 |
2003 |